The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

Eudralex Volume 2C Guidance on elements required to support the significant benefit in comparison with existing therapies of a new therapeutic indication in order to benefit from an extended (11 years) marketing protection period (November 2007)

Origin/Publisher:

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL http://ec.europa.eu/enterprise/index_en.htm

Document Type:
EC Guidance Document
Content:
This guidance outlines the level of evidence required to support extended marketing protection period based on a new therapeutic indication.

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK